UK Sovereign AI Fund Backs Potential Sciences to Speed Up Drug Discovery

The UK government has put its money behind a London startup that wants to rebuild the chemistry behind drug discovery. Potential Sciences, a company founded less than a year ago, has raised an eight-figure seed round with backing from Sovereign AI, the government's venture fund, and Stripe co-founder Patrick Collison.

The announcement came on 5 November 2026, and it shows how the government wants its Sovereign AI fund to work. The fund is not just writing cheques. It is also handing the startup time on the UK's national supercomputers.

Potential Sciences is trying to solve a problem that has slowed AI in drug discovery for years. Modern AI models are hungry for data, and in chemistry that data is expensive to produce. The company says the answer is to rebuild quantum chemistry, the maths that predicts how molecules behave, so it runs properly on modern graphics processors instead of the older computer chips it was written for.

What Potential Sciences actually does

Quantum chemistry is the set of calculations scientists use to work out how atoms and molecules interact. Those calculations sit at the heart of designing new medicines, because they can predict whether a candidate molecule will bind to a target in the body before anyone makes it in a lab.

The standard software for these calculations was built for central processing units, the general purpose chips in ordinary computers. It runs slowly at the scale AI needs, and producing the data in large volumes is costly. Potential Sciences says it has rewritten the core methods to run on graphics processing units, the chips that power modern AI, so highly accurate calculations become far cheaper to produce in large numbers.

The company claims its approach could cut the cost of the calculations used in chemical and drug design by about 100 times compared with current methods. That figure is the company's own estimate, and it has not been independently verified.

Potential Sciences was founded in November 2025 by Hatem Helal, a doctor and former executive at Graphcore, the British chip designer later acquired by SoftBank. Helal spent his career building the software layer between quantum chemistry and modern hardware.

Who is backing the round

Sovereign AI led the government side of the round, but it is far from the only investor. The venture firms in the round include Twin Path Ventures, Odyssey, Portfolio Ventures, Blue Wire Capital, rule30, Nauta Capital and Lightfield Equity.

Two well known angel investors also joined. Patrick Collison, the co-founder and chief executive of Stripe, took part in the round. So did Chris Gibson, the co-founder of Recursion. The exact amount raised and the company's valuation were not disclosed, which is normal for a seed round of this kind.

Sovereign AI's investment partner, Josephine Kant, said the fund was backing the company because high quality chemistry data is one of the biggest bottlenecks in AI driven scientific research. By rebuilding the software, she argued, the team can generate accurate scientific data at a reported 100 times lower cost than traditional methods.

The government framed the work in terms of patients. In its announcement it pointed to diseases such as cancer and Parkinson's, and to rarer conditions that are currently too expensive for drug makers to pursue.

Supercomputer time is part of the deal

The part of the deal that sets Sovereign AI apart from an ordinary venture fund is the compute. Alongside the investment, Potential Sciences gets access to the AI Research Resource, the UK's national fleet of advanced supercomputers, including the Isambard-AI system in Bristol.

That matters because the company's plan depends on volume. To train useful AI models for chemistry, it needs to generate millions of highly accurate calculations for models to learn from.

Sovereign AI was launched on 16 April 2026 as a 500 million pound fund that the government said would operate like a venture capital firm, helping promising UK based AI companies grow and compete globally.

The Potential Sciences deal follows the recent Budget, which added 140 million pounds of extra support for Sovereign AI. That included 60 million pounds for investments and 80 million pounds for a research and development procurement scheme.

Why chemistry, and why now

Drug discovery is one of the oldest promises of AI, and one of the slowest to deliver. AI models that design molecules are only as good as the data they train on, and much of the chemical record comes from decades of lab experiments that were never designed to feed a machine learning model.

Potential Sciences is betting that data generated from physics, computed cheaply enough on graphics processors, can supply the next dataset instead. If the calculations are accurate and cheap, the company argues, AI models can learn chemistry from first principles rather than from a patchy historical record.

It is a big claim, and it is still unproven at scale. The company has not published results from its models, and it has announced no drug candidates or pharmaceutical partnerships yet.

What happens next

For Potential Sciences, the next step is to turn the funding into results. The company will use the money and the supercomputer time to generate large volumes of chemistry calculations. The test will be whether those models can help researchers design real molecules faster and more cheaply than current methods allow.

For the rest of the UK's AI sector, the message is that the fund is open for business and willing to back deep technical bets. Whether that combination produces a breakthrough in drug discovery is a question only the science can answer.

Frequently Asked Questions

What is Potential Sciences?

Potential Sciences is a London based startup founded in November 2025 by former Graphcore executive Hatem Helal. It rebuilds quantum chemistry software to run on graphics processors, aiming to generate accurate chemistry data cheaply enough for AI models to learn from, with the goal of speeding up drug and chemical design.

What is the UK Sovereign AI fund?

Sovereign AI is the UK government's venture fund, launched in April 2026 with 500 million pounds. It invests in promising UK based AI companies and also gives them access to national supercomputer infrastructure through the AI Research Resource, including the Isambard-AI system in Bristol.

How much did Potential Sciences raise?

The company raised an eight-figure seed round, meaning tens of millions of pounds or dollars, but the exact amount and the company's valuation were not disclosed. Backers included Sovereign AI, seven venture firms and angel investors Patrick Collison of Stripe and Chris Gibson of Recursion.